Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective
Artificial Intelligence (AI) has the disruptive potential to transform patients’ lives via innovations in pharmaceutical sciences, drug development, clinical trials, and manufacturing. However, it presents significant challenges, ethical concerns, and risks across sectors and societies. AI’s rapid a...
Saved in:
Main Authors: | Fahimeh Mirakhori, Sarfaraz K. Niazi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/18/1/47 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
AI technologies in education: Regulatory frameworks at the international, regional and national level
by: Ignjatović Gordana
Published: (2024-01-01) -
Charles Marck, Sur les routes que j’ai parcourues
by: Laurence Montel
Published: (2022-10-01) -
Agentic AI: Autonomous Intelligence for Complex Goals—A Comprehensive Survey
by: Deepak Bhaskar Acharya, et al.
Published: (2025-01-01) -
Study of Regulatory and Institutional Framework for the Relocation of the National Capital in Indonesia
by: Arif Hidayat, et al.
Published: (2024-12-01) -
A Comprehensive Review on Limitations of Autonomous Driving and Its Impact on Accidents and Collisions
by: Amit Chougule, et al.
Published: (2024-01-01)